Skip to main content

Murad Hussain is an experienced trial lawyer who represents life sciences companies, healthcare providers, and others in all stages of criminal prosecutions, government-facing litigation, investigations by the U.S. Department of Justice (DOJ) and U.S. Department of Health Office of Inspector General (HHS-OIG), administrative proceedings before the Centers for Medicare and Medicaid Services (CMS), and internal compliance reviews. Murad has successfully defended clients in federal criminal jury trials, won dismissals of civil False Claims Act (FCA) qui tam cases, and secured declinations and no-fault settlements for individuals and companies under investigation by Main Justice, U.S Attorney’s Offices, HHS-OIG, and state Attorneys General. Murad’s practice focuses on representing entities, executives, and physicians in criminal healthcare fraud, civil FCA, and Anti-Kickback Statute (AKS) matters concerning marketing and pricing practices, genetic and diagnostic testing, private equity investment, regulatory compliance, and medical necessity disputes. Murad also counsels public figures, law firms, lobbyists, non-profit organizations, and others on Foreign Agents Registration Act (FARA) compliance and DOJ enforcement.

Murad has been recognized by The Legal 500 as a “Next Generation Partner” for healthcare and life sciences matters and by D.C.’s Best Lawyers for white collar criminal defense and FCA qui tam defense. He serves on the firm’s Pro Bono Committee, as the partner editor for the firm’s Enforcement Edge blog, and as an Adjunct Professor of trial practice at the Georgetown University Law Center. He also speaks regularly at conferences and other forums about using business data to promote internal compliance and counter the government's use—and misuse—of data analytics and statistics during investigations and trial.

Murad served as a law clerk to the Honorable Ellen Segal Huvelle of the U.S. District Court for the District of Columbia. He earned his law degree from Yale Law School, where he received the Potter Stewart Prize for best moot court team and the President’s Public Service Fellowship. Before law school, he worked as a creative executive at a Hollywood studio-based production company.

Experience

  • Pharmaceutical innovators, in winning dismissals of two False Claims Act qui tam suits concerning Plavix promotional activities, and in litigating related federal and state appeals. U.S. ex rel. JKJ Partnership 2011 LLP v. Sanofi Aventis, U.S. LLC, et al., No. 3:11-CV-6476, 2021 WL 5002715 (D.N.J. Oct. 28, 2021), on remand from 974 F.3d 228 (3d Cir.), after certified question answered by 226 A.3d 1117 (Del. 2020), upon certification from 2019 WL 10271190 (3d Cir. 2019), on appeal from 315 F. Supp. 3d 817 (DNJ 2018); U.S. ex rel. Dickson v. Bristol-Myers Squibb Co., et al., 332 F. Supp. 3d 927 (D.N.J. 2017).
  • Biopharmaceutical company, in defending against a corporate relator’s False Claims Act qui tam suit concerning nurse educator and reimbursement services. U.S. ex rel. CIMZNHCA LLC v. UCB Inc., 970 F.3d 835 (7th Cir. 2020) (ordering dismissal over relator’s objections).
  • Global healthcare company, in a DOJ investigation of Anti-Kickback Statute and price reporting compliance by pharmacy benefit managers (PBMs).
  • Biopharmaceutical company, in conducting an internal review of Lacey Act compliance concerning research animal transactions.
  • Various life sciences companies, in bringing administrative challenges to Medicare civil monetary penalty determinations and negotiating nuisance-value no-fault settlements. 
  • Multiple pharmaceutical companies, in responding to third-party subpoenas in civil FCA qui tam litigation.
  • Various medical device companies, in advising on Administrative Procedure Act litigation challenges to Medicare rulemaking.
  • Pharmaceutical company, in advising on state anti-kickback laws related to consumer marketing.
  • Life sciences company, in advising on internal compliance review of physician utilization data. 

Perspectives

Help Wanted: DOJ Seeks Cooperators To Address Corporate Crime by Offering Leniency
Enforcement Edge: Shining Light on Government Enforcement
Corporate Compliance & Self-Disclosure: A Conversation with DOJ’s Health Care Fraud Unit
Speaker, Health Care Compliance Association (HCCA)'s annual Compliance Institute
“Stark” Differences: DOJ’s Renewed Focus on Stand-Alone Stark Law Violations
Qui Notes: Unlocking the False Claims Act
“Willfulness” as “Knowledge of Illegality”: Second Circuit Adopts Prevailing Federal AKS Scienter Interpretation While Reviving State FCA Claims Over Potentially Different State AKS Scienter Standards
Qui Notes: Unlocking the False Claims Act
Legal Jeopardy: What are our Compliance Risks in the OBL Setting?
Panelist, Society of Interventional Radiology 2024 Annual Scientific Meeting
More

Recognition

Best Lawyers
Qui Tam Law (DC) (2021-2024)
Criminal Defense: White Collar (DC) (2023)
The Legal 500 U.S.
"Next Generation Partner" Healthcare: Life Sciences (2020-2023)
Healthcare: Life Sciences (2021-2022)
Healthcare: Service Providers (2021)
Washington, DC Super Lawyers
"Rising Star"Criminal Defense: White Collar; Government Contracts; Health Care; Civil Litigation: Defense (20142017)

Credentials

Education

  • J.D., Yale Law School
  • A.B., Harvard College, magna cum laude

Admissions

  • District of Columbia
  • California
  • Virginia
  • U.S. Court of Appeals for the District of Columbia Circuit
  • U.S. Court of Appeals for the Third Circuit
  • U.S. Court of Appeals for the Fourth Circuit
  • U.S. Court of Appeals for the Eleventh Circuit
  • U.S. District Court, District of Columbia
  • U.S. District Court, Central District of California
  • U.S. District Court, Eastern District of Virginia

Clerkships

  • U.S. District Court, District of Columbia, The Honorable Ellen Segal Huvelle
Overview